Aolirui® is the commercial brand name of Dexlansoprazole for Injection, a proton pump inhibitor developed by Jiangsu Aosaikang Pharmaceutical. It suppresses gastric acid secretion by irreversibly inhibiting the H+/K+-ATPase on gastric parietal cells, raising intragastric pH rapidly and persistently.
Main Indications
Treatment of duodenal ulcer;
Treatment of erosive or ulcerative gastroesophageal reflux disease;
For the treatment of pathological hypersecretory conditions including Zollinger-Ellison syndrome.
Clinical Research
A multicenter, randomized controlled Phase III trial in China confirmed that intravenous dexlansoprazole achieves rapid and sustained gastric acid inhibition for patients who cannot take oral PPI agents;
Registration clinical studies demonstrated non-inferior acid-suppressive effect compared with other intravenous proton pump inhibitors;
Real-world studies showed good efficacy for acute upper gastrointestinal bleeding with controllable adverse events.
Common Side Effects
Severe but important risks: Severe allergic reactions, hypomagnesemia;
Common mild adverse reactions: Headache, diarrhea, nausea, injection site pain and elevated liver enzymes.
Approval Status in China
Original drug Aolirui® (Dexlansoprazole for Injection, specification:15mg per vial) was officially approved for marketing in China in 2024. It is currently a prescription proton pump inhibitor drug.
Buy Aolirui (Dexlansoprazole for Injection) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
